Clinical Trial Update: A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting [Phase 3]

View source ↗

Summary

Phase 3 trial comparing neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer after multiple prior HER2-direc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)
• neratinib (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: HER2+ Metastatic Breast Cancer (MBC) | Phase 3 | Status: COMPLETED | Results posted: 2019-12-11